9149
|
ETCTN
|
Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
9466
|
ETCTN
|
Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
9571
|
ETCTN
|
A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
9608
|
ETCTN
|
A Phase I Trial of ABT-263 (Navitoclax); a Bcl-2 inhibitor; and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
9653
|
ETCTN
|
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Unrothelial Carcinoma of the Bladder
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
9671
|
ETCTN
|
Exceptional Responders Pilot study: Molecular profiling of tumors from cancer patients who are Exceptional responders
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
9672
|
ETCTN
|
A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
9673
|
ETCTN
|
PART A: A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal PART B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
9676
|
ETCTN
|
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
9681
|
ETCTN
|
A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors.
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|